drugset / Trial / NCT02679560

Effects of Liposomal Bupivacaine for Acute Pain in Hip and Femur Fractures

NCT02679560

RandomizedParallel-groupSingle-blindTreatment

Summary

This is an investigator-initiated, single-center, randomized, patient blinded, controlled trial. The purpose of this study is to compare the effect of a fascia iliaca compartment block (FICB) using 0.2% ropivacaine vs. liposomal bupivacaine in patients with femur and/or hip fractures admitted to the University of California Davis Medical Center (UCDMC). The primary endpoint will be the total opioid requirements during the 96 hour randomization period with secondary endpoints including total daily opioid requirements for days 1-4, duration of effect and objective pain scores using the numeric rating scale (NRS) during their hospital stay.

Timeline

Start
2017-10-01
Primary completion
2019-11-01
Completion
2019-11-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Bupivacaine Other / unclassified Other
Comparator Ropivacaine Other / unclassified 0.2 % Other

Indications

No indication recorded.